Neonatal Jaundice - Phototherapy Thresholds and Workup

Key Points

• Interpret bilirubin by age in hours, gestational age, and neurotoxicity risk factors.
• Jaundice in the first 24 hours requires prompt evaluation for pathologic causes.
• Use serum bilirubin to make treatment decisions when screening values are near threshold.
• Intensive phototherapy is first-line treatment when the AAP age-specific threshold is reached.
• Conjugated hyperbilirubinemia is abnormal and requires evaluation for cholestasis.
• Escalate care before the exchange threshold is reached when bilirubin is approaching a dangerous level.
• Signs of acute bilirubin encephalopathy require emergency exchange-transfusion capability.

Algorithm

1. Determine gestational age, exact postnatal age in hours, feeding status, weight change, and neurotoxicity risk factors.
2. Measure transcutaneous or serum bilirubin and plot it against the current AAP threshold.
3. If early, rapidly rising, or unexpectedly high, evaluate for hemolysis, G6PD deficiency, infection, bruising, and other causes.
4. Start intensive phototherapy at the indicated threshold while supporting feeding and hydration.
5. Repeat bilirubin according to proximity to exchange threshold and rate of rise.
6. If the escalation threshold is reached, move to a higher-acuity setting, continue intensive phototherapy, and prepare for exchange if needed.
7. Stop phototherapy only when the bilirubin is safely below threshold and rebound risk is addressed.
8. Arrange exact post-discharge bilirubin and feeding follow-up based on the infant's risk.

Clinical Synopsis & Reasoning

Unconjugated hyperbilirubinemia is common in newborns because bilirubin production is high and hepatic conjugation and enterohepatic handling are immature. Most jaundice is physiologic, but severe unconjugated bilirubin can cross the blood-brain barrier and cause acute bilirubin encephalopathy or kernicterus. Visual estimation alone is unreliable, especially across different skin tones. The bilirubin value must be interpreted by exact age in hours and gestational age rather than by a single universal cutoff. The 2022 AAP guideline applies to infants born at 35 weeks gestation or later and uses separate phototherapy and exchange thresholds based on gestation and neurotoxicity risk factors.

Jaundice in the first 24 hours is pathologic until evaluated. Rapid bilirubin rise, anemia, reticulocytosis, positive direct antiglobulin testing, or family history of hemolytic disease suggests increased bilirubin production. ABO or Rh isoimmunization, G6PD deficiency, hereditary spherocytosis, bruising, cephalohematoma, and polycythemia are important causes. Poor intake can produce suboptimal-intake jaundice with weight loss and decreased stooling. Breast-milk jaundice can persist in an otherwise thriving infant but remains a diagnosis made after more concerning causes are considered. Conjugated hyperbilirubinemia is never physiologic and points toward cholestatic or hepatobiliary disease.

Neurotoxicity risk factors lower treatment thresholds. These include lower gestational age, isoimmune hemolytic disease, G6PD deficiency or other hemolysis, sepsis, and significant clinical instability. Neurologic signs such as poor feeding, lethargy, hypotonia followed by hypertonia, high-pitched cry, retrocollis, opisthotonus, or apnea require immediate escalation. A total bilirubin near the exchange threshold is a medical emergency even before symptoms appear. Because G6PD deficiency can produce sudden severe rises and may not be predicted by ethnicity alone, clinicians should maintain a low threshold for testing when the pattern is unexplained or severe.

Treatment Strategy & Disposition

Measure bilirubin before discharge according to newborn-care standards and arrange follow-up based on how close the value is to the phototherapy threshold and on feeding and gestational risk. Transcutaneous bilirubin is useful for screening; obtain a total serum bilirubin when the transcutaneous value is high, near a treatment threshold, or otherwise requires confirmation under the AAP pathway. If phototherapy is indicated, use intensive narrow-spectrum blue-light therapy with adequate irradiance and maximal safe skin exposure while maintaining temperature and hydration. Continue feeding; breastfeeding should usually continue, with lactation support and supplementation when intake is inadequate or weight loss is excessive.

When bilirubin reaches the AAP escalation-of-care threshold, which is below the exchange-transfusion threshold, transfer or manage in a setting capable of urgent exchange transfusion. Use intensive phototherapy continuously, obtain frequent serum bilirubin measurements, establish IV access, and evaluate hemolysis and underlying disease. IVIG may be considered in selected isoimmune hemolytic disease when bilirubin continues to rise despite intensive phototherapy and reaches escalation levels, but benefit is uncertain and adverse effects exist; it is not routine for every infant with a positive DAT. Exchange transfusion is required for bilirubin at or above the exchange threshold or for signs of acute bilirubin encephalopathy.

After phototherapy, assess rebound risk according to age at treatment, hemolysis, gestational age, and bilirubin level at discontinuation. Infants treated very early or with hemolytic disease need closer repeat testing. Every discharge plan should connect the bilirubin trajectory with feeding, weight, stooling, and a precise follow-up time. A generic instruction to see the pediatrician sometime in the next week is unsafe for a newborn whose bilirubin is close to treatment threshold.

Epidemiology / Risk Factors

• Visible jaundice occurs in a majority of newborns during the first week of life.
• Most cases are benign and resolve without treatment.
• Prematurity, hemolysis, G6PD deficiency, and feeding problems increase risk of severe hyperbilirubinemia.
• Universal predischarge bilirubin assessment and risk-based follow-up reduce the chance of severe unrecognized disease.

Investigations

Risk Factors

Pharmacology

Prognosis / Complications

• Infants treated before neurologic injury generally have an excellent prognosis.
• Acute bilirubin encephalopathy can progress to permanent kernicterus with hearing loss, abnormal movement, gaze abnormalities, and developmental impairment.
• Hemolytic disease can produce rebound hyperbilirubinemia and later anemia even after the bilirubin is controlled.
• Persistent direct hyperbilirubinemia has a prognosis determined by the underlying hepatobiliary disease and requires timely workup.

Patient Education / Counseling

• Explain the infant's actual bilirubin value, threshold, and next testing time in concrete terms.
• Review feeding frequency, latch or milk transfer, urine output, stool transition, and weight trajectory.
• Seek urgent care for poor feeding, marked sleepiness, a high-pitched cry, arching, fever, or jaundice that is rapidly deepening.
• Do not place an infant in direct sunlight as a substitute for prescribed phototherapy.
• Families with G6PD deficiency should be told about oxidant exposures and the need to inform future clinicians.

Notes

The 2022 AAP guideline deliberately moved away from one-size-fits-all bilirubin numbers. Two infants with the same serum bilirubin can have different treatment thresholds because one is 37 weeks with hemolysis and the other is 40 weeks and clinically well. Any reference article that presents a single phototherapy cutoff without age and gestation context is therefore unsafe.

Follow-up timing is part of bilirubin treatment. Many severe cases emerge after the birth hospitalization, when intake is changing and bilirubin is still rising. The most useful discharge plan tells the family when the next bilirubin or clinical assessment will occur and ensures that appointment can actually happen.

References

1. American Academy of Pediatrics: 2022 Clinical Practice Guideline Revision, Hyperbilirubinemia — Link
2. American Academy of Pediatrics: Technical Report on Hyperbilirubinemia — Link